Archer Materials Limited, a pioneering semiconductor company at the forefront of advancing the quantum computing and medical diagnostics industries, has achieved a groundbreaking milestone. In a recent development, Archer demonstrated multiplexing readout for its cutting-edge Biochip graphene field effect transistor ("gFET") device.
This remarkable achievement involves the successful utilization of single-device multiplexing, utilizing four advanced gFETs as sensors. These sensors have been seamlessly integrated into the Archer advanced Biochip platform, which was initially unveiled on September 14, 2023. This breakthrough is of immense significance as Archer's ultimate aim is to harness the multiplexing capability within the Biochip for the simultaneous testing of multiple diseases on a single chip.
Archer has invested in designing and developing new hardware and software systems that enable the simultaneous readout of signals from four advanced gFET sensors on a single chip. This is a significant leap forward from the earlier generation of the Biochip system, which was introduced on November 16, 2022, and was limited to activating one sensor at a time.
The newly enhanced Biochip system, equipped with multiplexing capabilities, not only offers automated, hands-free operation but also integrates liquid handling automation and data acquisition. Archer's in-house software facilitates real-time display of all single and time series measurements from the four gFET sensors, all at once.
Commenting on this groundbreaking demonstration of multiplexing readout, Dr. Mohammad Choucair, the CEO of Archer Materials Limited, expressed his excitement, saying:
"Archer is now able to demonstrate readout, or a signal, from multiple graphene sensors and liquid samples coming from the Biochip, which is a step-change in advancing towards the potential to sense multiple disease samples at once, on a single chip. The progress made by the Archer team to demonstrate multiplex detection, and the support of our commercial foundry partners in the manufacture of Archer’s Biochip devices, will be applied towards the function and operation of the Biochip in targeting biologically relevant molecules. Moving testing for diseases from the lab onto a chip has the potential to create better access to healthcare for those who might not have it and can therefore help improve patient outcomes.
#QuantumComputing #MedicalDiagnostics #Semiconductors #BiochipTechnology #GrapheneSensors #Innovation #HealthcareTech #TechAdvancements #Multiplexing #HealthcareAccess #ArcherMaterials
HYUNDAI TRANSYS
3wThank you for joining us in innovation.